These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34682890)

  • 41. [Efficacy and Management of Adverse Events of Ipilimumab Including Combination Therapy with Nivolumab].
    Uhara H; Itakura E
    Gan To Kagaku Ryoho; 2019 Jun; 46(6):1017-1026. PubMed ID: 31273168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.
    Gupta R; Ornstein MC; Li H; Allman KD; Wood LS; Gilligan T; Garcia JA; Merveldt DV; Hammers HJ; Rini BI
    Clin Genitourin Cancer; 2020 Dec; 18(6):429-435. PubMed ID: 32800717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nivolumab-induced thyroid dysfunction in patients with lung cancer.
    Ramos-Levi AM; Rogado J; Sanchez-Torres JM; Colomer R; Marazuela M
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Jan; 66(1):26-34. PubMed ID: 29910159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A Case of Metachronous Occurrence of Interstitial Pneumonitis and Hypophysitis Following Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma].
    Hayase T; Washino S; Mayumi S; Yazaki K; Nakamura Y; Oshima M; Konishi T; Saito K; Miyagawa T
    Hinyokika Kiyo; 2021 Jun; 67(6):239-243. PubMed ID: 34265899
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
    Baldini C; Martin Romano P; Voisin AL; Danlos FX; Champiat S; Laghouati S; Kfoury M; Vincent H; Postel-Vinay S; Varga A; Vuagnat P; Ribrag V; Mezquita L; Besse B; Hollebecque A; Lambotte O; Michot JM; Soria JC; Massard C; Marabelle A
    Eur J Cancer; 2020 Apr; 129():71-79. PubMed ID: 32143106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
    BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
    Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO
    Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
    Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
    J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management.
    Yanase T; Moritoki Y; Kondo H; Ueyama D; Akita H; Yasui T
    Urol Case Rep; 2021 Jan; 34():101508. PubMed ID: 33318935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.
    Carril-Ajuria L; Lora D; Carretero-González A; Martín-Soberón M; Rioja-Viera P; Castellano D; de Velasco G
    Clin Genitourin Cancer; 2021 Apr; 19(2):95-102. PubMed ID: 33189597
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report.
    Motonaga A; Nakanishi S; Tanaka K; Nishida S; Izumi K; Saito S
    Urol Case Rep; 2021 Sep; 38():101661. PubMed ID: 33868946
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
    Subudhi SK; Aparicio A; Gao J; Zurita AJ; Araujo JC; Logothetis CJ; Tahir SA; Korivi BR; Slack RS; Vence L; Emerson RO; Yusko E; Vignali M; Robins HS; Sun J; Allison JP; Sharma P
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11919-11924. PubMed ID: 27698113
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.
    Wang PF; Chen Y; Song SY; Wang TJ; Ji WJ; Li SW; Liu N; Yan CX
    Front Pharmacol; 2017; 8():730. PubMed ID: 29093678
    [No Abstract]   [Full Text] [Related]  

  • 56. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Taura M; Uchi R; Nakagawa T
    Oral Oncol; 2020 Feb; 101():104525. PubMed ID: 31863963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic Significance of Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Patients Treated With Immune-checkpoint-inhibitors.
    Yasuda Y; Fujiwara R; Oguchi T; Komai Y; Numao N; Yamamoto S; Oki R; Urasaki T; Takahashi S; Yonese J; Yuasa T
    Cancer Diagn Progn; 2023; 3(3):327-333. PubMed ID: 37168959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination immunotherapy of nivolumab plus ipilimumab in a lung cancer patient with Werner syndrome; a case report.
    Ikematsu Y; Izumi M; Katahira K; Ueno T; Moriuchi Y; Ose M; Noda N; Hara M; Otsuka J; Wakamatsu K; Kawasaki M
    Respir Med Case Rep; 2022; 37():101642. PubMed ID: 35360361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
    N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
    Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
    Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.